鼠重组血管紧张素转换酶2减轻实验性Alport综合征肾损伤
本研究在Col4a3基因敲除小鼠(Alport综合征模型)中,从4至7周龄经渗透泵给予鼠重组ACE2(0.5 mg/kg/天),发现治疗可减轻肾脏纤维化、炎症及TGF-β信号,并抑制TACE表达,提示外源性ACE2可改变肾脏血管紧张素肽代谢并减缓Alport综合征肾病进展。
要点
- 在Col4a3敲除小鼠中,鼠重组ACE2(0.5 mg/kg/天)从4至7周龄经渗透泵给药可减轻肾脏病理改变。
- 治疗组肾脏纤维化减轻,表现为COL1α1 mRNA表达下降、细胞外基质蛋白蓄积减少及TGF-β信号抑制。
- 治疗还降低促炎细胞因子表达、巨噬细胞浸润、炎症信号通路活化及血红素加氧酶-1水平,并抑制TACE表达。
核心结论
- 外源性ACE2治疗改变Col4a3敲除小鼠肾脏血管紧张素肽代谢并减缓Alport综合征肾病进展。
研究设计与样本
- 在Col4a3基因敲除小鼠(Alport综合征模型,以蛋白尿和进行性肾损伤为特征)中评估鼠重组ACE2的治疗效果。
- 鼠重组ACE2以0.5 mg/kg/天剂量从4周龄至7周龄经渗透泵给药。
主要发现
- 鼠重组ACE2治疗减轻肾脏病理改变,改善肾脏纤维化,表现为COL1α1 mRNA表达下降、细胞外基质蛋白蓄积减少及转化生长因子-β信号抑制。
- 鼠重组ACE2治疗降低Col4a3敲除小鼠中促炎细胞因子表达的增加、巨噬细胞浸润、炎症信号通路活化及血红素加氧酶-1水平。
- 鼠重组ACE2抑制肿瘤坏死因子-α转化酶(ACE2的负性调控因子)的表达,影响肾脏ACE2的更新。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Angiotensin-converting enzyme 2 (ACE2) is a monocarboxypeptidase in the renin-angiotensin system that catalyzes the breakdown of angiotensin II to angiotensin 1-7. We have reported that ACE2 expression in the kidney is reduced in experimental Alport syndrome but the impact of this finding on disease progression has not been studied. Accordingly, we evaluated effects of murine recombinant ACE2 treatment in Col4a3 knockout mice, a model of Alport syndrome characterized by proteinuria and progressive renal injury. Murine recombinant ACE2 (0.5 mg/kg/day) was administered from four to seven weeks of age via osmotic mini-pump. Pathological changes were attenuated by murine recombinant ACE2 treatment which ameliorated kidney fibrosis as shown by decreased expression of COL1α1 mRNA, less accumulation of extracellular matrix proteins, and inhibition of transforming growth factor-β signaling. Further, increases in proinflammatory cytokine expression, macrophage infiltration, inflammatory signaling pathway activation, and heme oxygenase-1 levels in Col4a3 knockout mice were also reduced by murine recombinant ACE2 treatment. Lastly, murine recombinant ACE2 influenced the turnover of renal ACE2, as it suppressed the expression of tumor necrosis factor-α converting enzyme, a negative regulator of ACE2. Thus, treatment with exogenous ACE2 alters angiotensin peptide metabolism in the kidneys of Col4a3 knockout mice and attenuates the progression of Alport syndrome nephropathy.
引用
- Bae EH, Fang F, Williams VR, et al. Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimental Alport syndrome. Kidney Int. 2017. PMID: 28249676. doi:10.1016/j.kint.2016.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。